Christine Hay
Concepts (121)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of publications
|
Most recent publication
|
Publications by all authors
|
Why?
|
|---|
T-Lymphocytes, Cytotoxic | 3 | 1998 | 52 |
Why?
|
HIV-1 | 4 | 1998 | 93 |
Why?
|
HIV Infections | 4 | 1998 | 136 |
Why?
|
Influenza Vaccines | 3 | 2006 | 70 |
Why?
|
Lymphocyte Activation | 1 | 1999 | 137 |
Why?
|
Hemagglutinin Glycoproteins, Influenza Virus | 2 | 2006 | 17 |
Why?
|
Vaccines, DNA | 2 | 2007 | 16 |
Why?
|
Flagellin | 1 | 2010 | 6 |
Why?
|
Hemagglutinins, Viral | 1 | 2010 | 11 |
Why?
|
Vaccinia virus | 1 | 2011 | 22 |
Why?
|
AIDS Vaccines | 1 | 2011 | 18 |
Why?
|
HIV Antibodies | 2 | 1999 | 16 |
Why?
|
Neutralization Tests | 2 | 1999 | 37 |
Why?
|
Polymyxin B | 1 | 2004 | 7 |
Why?
|
Gram-Negative Bacterial Infections | 1 | 2004 | 7 |
Why?
|
Drug Resistance, Multiple, Bacterial | 1 | 2004 | 12 |
Why?
|
Respiratory Tract Infections | 1 | 2004 | 57 |
Why?
|
Adult | 6 | 1999 | 1317 |
Why?
|
Receptors, Antigen, T-Cell, alpha-beta | 1 | 2001 | 18 |
Why?
|
Longitudinal Studies | 2 | 1999 | 195 |
Why?
|
Disease Progression | 2 | 1999 | 244 |
Why?
|
Placebos | 2 | 2010 | 110 |
Why?
|
Anti-Bacterial Agents | 1 | 2004 | 195 |
Why?
|
HLA-A2 Antigen | 1 | 1999 | 8 |
Why?
|
Gene Products, gag | 1 | 1999 | 14 |
Why?
|
Major Histocompatibility Complex | 1 | 1999 | 23 |
Why?
|
Epitopes, T-Lymphocyte | 1 | 1999 | 17 |
Why?
|
Hemagglutination Inhibition Tests | 2 | 2007 | 28 |
Why?
|
Fatal Outcome | 1 | 1999 | 86 |
Why?
|
Male | 7 | 1997 | 1553 |
Why?
|
Immunologic Memory | 1 | 1999 | 51 |
Why?
|
Lymphocytes | 1 | 1999 | 142 |
Why?
|
Cytotoxicity, Immunologic | 1 | 1998 | 54 |
Why?
|
Peptides | 1 | 1999 | 154 |
Why?
|
Middle Aged | 5 | 2004 | 1161 |
Why?
|
Baculoviridae | 2 | 2006 | 23 |
Why?
|
Young Adult | 2 | 2010 | 380 |
Why?
|
Nerve Degeneration | 1 | 1997 | 43 |
Why?
|
Cell Division | 1 | 1999 | 273 |
Why?
|
Phenotype | 1 | 1999 | 303 |
Why?
|
Double-Blind Method | 2 | 2007 | 274 |
Why?
|
Nerve Growth Factors | 1 | 1997 | 43 |
Why?
|
Humans | 9 | 1997 | 1856 |
Why?
|
Adolescent | 3 | 2007 | 891 |
Why?
|
Antibodies, Viral | 2 | 2006 | 104 |
Why?
|
Virus Replication | 1 | 1998 | 90 |
Why?
|
Neuroprotective Agents | 1 | 1997 | 60 |
Why?
|
Time Factors | 2 | 1999 | 896 |
Why?
|
Dopamine | 1 | 1997 | 62 |
Why?
|
Gene Therapy | 1 | 1997 | 89 |
Why?
|
Nerve Tissue Proteins | 1 | 1997 | 128 |
Why?
|
Genetic Vectors | 2 | 1997 | 139 |
Why?
|
Parkinson Disease | 1 | 1997 | 67 |
Why?
|
Mutation | 1 | 1999 | 340 |
Why?
|
Female | 5 | 2004 | 1643 |
Why?
|
Elastin | 1 | 1991 | 22 |
Why?
|
Gene Expression | 2 | 1997 | 291 |
Why?
|
Laminin | 1 | 1991 | 40 |
Why?
|
Receptors, Immunologic | 1 | 1991 | 36 |
Why?
|
Injections, Intramuscular | 1 | 2010 | 43 |
Why?
|
CD4 Lymphocyte Count | 1 | 2011 | 50 |
Why?
|
Vaccines, Synthetic | 1 | 2010 | 30 |
Why?
|
Drug Administration Schedule | 1 | 2011 | 191 |
Why?
|
C-Reactive Protein | 1 | 2010 | 54 |
Why?
|
Antibodies, Bacterial | 1 | 2010 | 50 |
Why?
|
Receptors, Cell Surface | 1 | 1991 | 115 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 1 | 2011 | 224 |
Why?
|
CD8-Positive T-Lymphocytes | 1 | 2011 | 91 |
Why?
|
Vaccination | 1 | 2010 | 92 |
Why?
|
Aged, 80 and over | 2 | 2004 | 599 |
Why?
|
CD4-Positive T-Lymphocytes | 1 | 2011 | 113 |
Why?
|
Immunodiffusion | 1 | 2007 | 30 |
Why?
|
Escherichia coli | 1 | 2010 | 143 |
Why?
|
Influenza B virus | 1 | 2007 | 16 |
Why?
|
Influenza A Virus, H3N2 Subtype | 1 | 2007 | 21 |
Why?
|
Cytokines | 1 | 2010 | 207 |
Why?
|
Maximum Tolerated Dose | 1 | 2006 | 18 |
Why?
|
Dose-Response Relationship, Immunologic | 1 | 2006 | 37 |
Why?
|
Vaccines, Inactivated | 1 | 2006 | 15 |
Why?
|
Influenza A Virus, H1N1 Subtype | 1 | 2007 | 27 |
Why?
|
Alcaligenes | 1 | 2004 | 1 |
Why?
|
Germany | 1 | 2004 | 21 |
Why?
|
Acinetobacter baumannii | 1 | 2004 | 6 |
Why?
|
Injections, Intravenous | 1 | 2004 | 105 |
Why?
|
Critical Illness | 1 | 2004 | 34 |
Why?
|
Administration, Inhalation | 1 | 2004 | 60 |
Why?
|
Drug Therapy, Combination | 1 | 2004 | 189 |
Why?
|
Aged | 2 | 2004 | 988 |
Why?
|
United States | 1 | 2011 | 604 |
Why?
|
Pseudomonas aeruginosa | 1 | 2004 | 33 |
Why?
|
Kidney Diseases | 1 | 2004 | 90 |
Why?
|
Clone Cells | 1 | 2001 | 92 |
Why?
|
Chronic Disease | 1 | 2001 | 267 |
Why?
|
Retrospective Studies | 1 | 2004 | 653 |
Why?
|
Glial Cell Line-Derived Neurotrophic Factor | 1 | 1997 | 6 |
Why?
|
Transgenes | 1 | 1997 | 56 |
Why?
|
Oxidopamine | 1 | 1997 | 21 |
Why?
|
PC12 Cells | 1 | 1997 | 27 |
Why?
|
Adenoviridae | 1 | 1997 | 60 |
Why?
|
Substantia Nigra | 1 | 1997 | 30 |
Why?
|
Treatment Outcome | 1 | 2004 | 661 |
Why?
|
Rats, Inbred F344 | 1 | 1997 | 80 |
Why?
|
Corpus Striatum | 1 | 1997 | 48 |
Why?
|
Galactosides | 1 | 1991 | 6 |
Why?
|
Receptors, Laminin | 1 | 1991 | 7 |
Why?
|
Membrane Fluidity | 1 | 1991 | 7 |
Why?
|
Lectins | 1 | 1991 | 18 |
Why?
|
Actin Cytoskeleton | 1 | 1991 | 14 |
Why?
|
Diffusion | 1 | 1991 | 49 |
Why?
|
Molecular Sequence Data | 1 | 1997 | 404 |
Why?
|
Video Recording | 1 | 1991 | 46 |
Why?
|
Binding, Competitive | 1 | 1991 | 109 |
Why?
|
Molecular Weight | 1 | 1991 | 154 |
Why?
|
Microscopy, Electron | 1 | 1991 | 178 |
Why?
|
Biological Transport | 1 | 1991 | 129 |
Why?
|
Ligands | 1 | 1991 | 116 |
Why?
|
Cattle | 1 | 1991 | 176 |
Why?
|
Neurons | 1 | 1997 | 195 |
Why?
|
Cell Membrane | 1 | 1991 | 170 |
Why?
|
Rats | 1 | 1997 | 530 |
Why?
|
Animals | 2 | 1991 | 1031 |
Why?
|
